Aadi Bioscience

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Aadi Bioscience sits in the top decile of US sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count).

9 total trials 3 currently recruiting 5 completed early-phase tilt top decile by trial count

Aadi Bioscience: 9 sponsored US clinical trials, 3 recruiting.

Aadi Bioscience sponsors 9 registered US clinical trials on ClinicalTrials.gov, 3 of them currently recruiting, and 5 completed. 0 of these trials are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Tumor, with 3 trials.

Top-decile sponsor footprint

Aadi Bioscience ranks in the top decile of sponsors by registered trial count (#1,458 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Open and recent trials

9 total, page 1 of 1

RECRUITING Phase 2

Trial of Nab-Sirolimus in Combination With Letrozole in Patients With Advanced or Recurrent Endometrioid Endometrial Cancer

NCT05997017
RECRUITING Phase 2

Trial of Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) of the Gastrointestinal Tract, Lung, or Pancreas Who Have Not Received Prior Treatment With mTOR Inhibitors

NCT05997056
RECRUITING Phase 1

Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment

NCT05661461
ACTIVE NOT RECRUITING Phase 2

Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)

NCT05103358
COMPLETED Phase 2

Nab-sirolimus in Recurrent High Grade Glioma and Newly Diagnosed Glioblastoma

NCT03463265
COMPLETED Phase 1

Nab-Sirolimus in Combination With FOLFOX & BEV as 1st Line Therapy in Patients With Advanced or Metastatic Colorectal Cancer

NCT03439462
COMPLETED Phase 1

Phase 1/1b Study With Nab-sirolimus for Patients With Severe Pulmonary Arterial Hypertension

NCT02587325
COMPLETED Phase 2

A Phase 2 Study of Nab-sirolimus (ABI-009) in Patients With Advanced Malignant PEComa

NCT02494570
COMPLETED Phase 1

Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer

NCT02009332

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 5

Therapeutic Areas

Tumor 3
Tumor, Solid 2
Cancer 2
High Grade Recurrent Glioma and Newly Diagnosed Glioblastoma 1
Endometrioid Endometrial Cancer 1
Endometrioid Tumor 1
Tumors 1
Pulmonary Neuroendocrine Tumor 1
Gastrointestinal Neuroendocrine Tumor 1
NET 1

What is open in the Aadi Bioscience pipeline

3 recruiting of 9 indexed (33% open); 5 completed (56%).

Phase mix: 0 late (III/IV) vs 9 early (I/II) (early-phase heavy).

Top condition: Tumor (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Aadi Bioscience: open-pipeline peers nationwide

Peers matched on 9 registered trials and 33% open enrollment, not the therapeutic-area sidebar.

Aadi Bioscience sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 246810 0%10%20%30%40%50% Total trials Recruiting share Aadi Bioscience4D Molecular Therapeutics9 Meters BiopharmaAblynx, a Sanofi companyAcacia PharmaAaron CookAbivax S.A.Actuated MedicalAdagio Medical
Aadi Bioscience sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aadi Bioscience sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 9 trials (± recruiting share)

Sponsors near 33% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Aadi Bioscience page

9 registered trials is a research-attention snapshot, not an endorsement of Aadi Bioscience or any single study.

  • 3 of Aadi Bioscience's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Tumor is the condition Aadi Bioscience studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Tumor trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aadi Bioscience pipeline card: 9 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.